Clinical trials: Malignant Tumor
Pancreatic Cancer
Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)
The aim of this study is to explore the efficacy and safety of a new combination regimen of GnP regimen, SBRT and the anti-PD-1/VEGF bis-antibody, Ivonescimab, in patients with recurrent metastatic advanced pancreatic cancer.
- Trial name
- NCT06991491
- Testing
- GnP in combination with Ivonescimab and SBRT
- Volunteers
- 29 people
- Sponsor
- West China Hospital
Human Papillomavirus Infection, HPV
Human Papillomavirus in Young People Epidemiological Research 4
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV.
- Conditions
- Human Papillomavirus Infection, HPV, HPV Infection, Anal Cancer
- Trial name
- HYPER4 (NCT05587738)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Monash University
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Cholangiocarcinoma, Hilar
Volume-Restricted Resection for Perihilar Cholangiocarcinoma
The goal of this observational study is to learn about the safety and long-term outcomes of volume-restricted liver resection in patients with perihilar cholangiocarcinoma (pCCA) who have an insufficient future liver remnant…
- Trial name
- NCT07149558
- Volunteers
- 300 people
- Sponsor
- Yongjun Chen
Metastatic Solid Tumor
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic…
- Trial name
- NCT04898543
- Testing
- M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunityBio, Inc.
Spinal Tumor, Spinal Disorder
Duke Spine Outcome Study (DSOS)
The primary goal of this registry is to increase the knowledge about spine tumors and other spine disorders to guide appropriate management strategies for the future.
- Trial name
- DSOS (NCT04217525)
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- Duke University
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Unspecified Adult Solid Tumor, Protocol Specific
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of lurtotecan liposome in treating patients who have…
- Trial name
- NCT00003891
- Testing
- lurtotecan liposome
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- NCIC Clinical Trials Group
Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen…
- Conditions
- Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
- Trial name
- NCT06866574
- Testing
- Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli), Aluminum Adjuvant
- Where
- 4 sites in China
- Volunteers
- 9,300 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Metastatic Cancer
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00028652
- Testing
- interleukin-12 gene
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Cervical Cancer, Endometrial Cancer
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00842452
- Testing
- topotecan hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Steven Waggoner, MD
Solid Tumor
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project Coordinator, but will not be recruiting locally.
- Trial name
- NCT01683149
- Testing
- Topotecan, Sorafenib
- Where
- 9 sites in United States
- Volunteers
- 13 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer, Colo-rectal Cancer
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance.
- Conditions
- Colorectal Cancer, Colo-rectal Cancer, ctDNA, Gastro-Intestinal Disorder
- Trial name
- NCT04084249
- Testing
- ctDNA-analysis, Intensified Follow-up Schedule
- Where
- 10 sites in Denmark
- Volunteers
- 359 people
- Sponsor
- Claus Lindbjerg Andersen
Csf Leakage
Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery
A 65 year old female participant , right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, the participant underwent an MRI and it was found a sellar lesion that compressed the optic…
- Trial name
- NCT03280849
- Testing
- Implant of bilaminar chitosan scaffold
- Where
- Mexico
- Volunteers
- 1 people
- Sponsor
- University of Guadalajara
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
Primary Brain Tumor
Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry
The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions.
- Trial name
- NCT02389855
- Testing
- NeuroBlate® System Therapy
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Monteris Medical
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
This is a phase Ib trial with SAR439459, a TGF-beta inhibitor, in combination with cemiplimab, a PD-L1 inhibitor, in patients with solid tumors that have spread to other places in the body (advanced) or cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04729725
- Testing
- Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.
- Trial name
- NCT07843550
- Testing
- Larotrectinib, Pembrolizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Neoplasm, Malignant, Colo-rectal Cancer
Endoscopic Full-Thickness Resection In Colon
Endoscopic full-thickness resection (EFTR) in the colon using an over-the-scope clip (OTSC) as a closure mechanism is a recent technique that allows the endoscopic resection of colonic lesions that are poor candidates for…
- Conditions
- Colon Neoplasm, Malignant, Colo-rectal Cancer, Colonic Cancer, Colonic Adenoma
- Trial name
- EFTRICOM (NCT03803891)
- Testing
- Endoscopic full-thickness resection
- Where
- 17 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Hepatocellular Carcinoma
Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.
- Trial name
- NCT00746590
- Testing
- Prolarix (tretazicar co-administered with caricotamide)
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- BTG International Inc.